<DOC>
	<DOCNO>NCT00114491</DOCNO>
	<brief_summary>Recent study support hypothesis aortic stenosis ( AS ) develop due atherosclerosis affect aortic valve endothelium . The study ’ aim ass Rosuvastatin hemodynamic progression inflammatory marker AS treat low-density lipoprotein ( LDL ) patient AS accord National Cholesterol Education Program Adult Treatment Panel III ( NCEP-ATPIII ) guideline one year .</brief_summary>
	<brief_title>Rosuvastatin Affecting Aortic Valve Endothelium</brief_title>
	<detailed_description>Background : Recent retrospective study support hypothesis statin slow progression aortic stenosis . The aim study assess effect Rosuvastatin hemodynamic progression aortic stenosis treat patient aortic stenosis elevate LDL-cholesterol 18 month . Methods : We perform open-label , prospective study evaluate 121 consecutive patient asymptomatic moderate severe aortic stenosis ( AVA≥ 1.0 cm2 ) , ( mean age 73.7±8.9 year ; 57 men 64 woman ) , treat without Rosuvastatin accord NCEP-ATPIII guideline . Echocardiographic , serum lipid , inflammatory marker measure baseline every 6 month 18 month .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Asymptomatic AS Normal ejection fraction Elevated LDL &gt; 130 mg/dl Echocardiographic evidence rheumatic mitral valve disease , Previous statin therapy , Congenital heart disease ( bicuspid aortic valve ) , Subaortic obstruction , Creatinine ≥ 2,0 mg/dl ( avoid potential confounder elevate serum [ CaP04 ] ) , Evidence liver disease , Greater mild aortic regurgitation previous aortic valve surgery</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Statins</keyword>
	<keyword>Hypercholesterolemia</keyword>
</DOC>